Iv%2520gentamicin

# IV Gentamicin ## Overview Gentamicin is an aminoglycoside antibiotic that exerts bactericidal activity by irreversibly binding to the 30S ribosomal subunit, inhibiting protein synthesis. It demonstrates concentration-dependent killing and a significant post-antibiotic effect. ## Primary Indications * Serious Gram-negative infections (e.g., *Pseudomonas aeruginosa*, *Enterobacter*, *Klebsiella*). * Synergistic treatment for Gram-positive endocarditis (e.g., *Staphylococcus*, *Enterococcus*). * Empiric treatment for sepsis or complicated urinary tract infections. ## Adult Dosing * **Traditional Dosing:** 1–2.5 mg/kg every 8–12 hours. * **Extended Interval Dosing (EID):** 5–7 mg/kg every 24 hours (based on nomograms like Hartford or Sawchuk-Zaske). * **Synergy (Endocarditis):** 1 mg/kg every 8 hours. * *Note: Dosing should always be based on Ideal Body Weight (IBW) or Adjusted Body Weight (AdjBW) if obese.* ## Pediatric Dosing * **Neonates (0–7 days):** 2.5–4 mg/kg every 12–24 hours (highly weight and gestational age dependent). * **Infants/Children:** 2.5 mg/kg every 8 hours. * *Note: Pediatric dosing is highly variable; clinical practice must adhere to institutional protocols or weight/age-based nomograms.* ## Dose Adjustments * **Renal Impairment:** Required for both traditional and EID regimens. Calculate CrCl; decrease dose or extend interval based on serum creatinine and therapeutic drug monitoring (TDM). * **Obesity:** Use adjusted body weight (IBW + 0.4 × [actual weight - IBW]) to prevent over-dosing. ## Contraindications * Known hypersensitivity to gentamicin or other aminoglycosides. * Use with extreme caution in patients with neuromuscular disorders (e.g., myasthenia gravis) or concurrent nephrotoxic/ototoxic drugs. ## Adverse Effects * **Nephrotoxicity:** Usually reversible; manifests as rising serum creatinine. * **Ototoxicity:** Often irreversible; involves vestibular (vertigo, ataxia) or auditory (tinnitus, hearing loss) damage. * **Neuromuscular Blockade:** Rare, but can lead to respiratory paralysis, especially in high doses or with rapid infusion. ## Key Drug Interactions * **Nephrotoxins:** Increased risk with vancomycin, amphotericin B, NSAIDs, cyclosporine, and cisplatin. * **Loop Diuretics:** Increased risk of ototoxicity (e.g., furosemide). * **Neuromuscular Blockers:** Potential for prolonged paralysis. ## Monitoring * **Renal Function:** Monitor serum creatinine and BUN daily. * **TDM (Traditional):** Measure peak (post-distribution) and trough (pre-dose). * **TDM (EID):** Utilize random drug level monitoring (nomogram-dependent, typically 6–14 hours post-infusion). * **Audiometry:** Consider in patients on long-term therapy (>10 days). ## Clinical Pearls * Infusion should be administered over 30 minutes to minimize risk of infusion-related adverse effects. * "Synergy" doses for endocarditis are typically low-dose and should be monitored to avoid therapeutic troughs, which increase toxicity risk without added benefit. * EID is preferred in patients with normal renal function as it optimizes the peak-to-MIC ratio while minimizing accumulation. * *Disclaimer: Gentamicin dosing is highly dependent on institutional protocols. Always verify specific dosing nomograms, local resistance patterns, and patient-specific renal function before prescribing.* *** **Educational Disclaimer:** This information is for educational purposes and does not replace professional clinical judgment. Always verify current prescribing information, institutional guidelines, and drug compatibility before administration.